Press Releases

WuXi XDC(stock code: 2268.HK), a leading global Contract, Resea­­rch, Development, and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, announced it has received four awards from industry’s leading and premier institutions and media outlets: Jiemian “2023 Evergreen Award – ADC Pharmaceutical CRDMO Service Award”, Zhitong Finance “The Most Popular New Public Company with investors”, Sina Finance 2023 Pharmaceutical Industry Golden Kylin Award “The Most Potential Hong Kong Stock Pharmaceutical Company”, Gelonghui “Annual Outstanding Growth Force IPO Award”. These awards recognized WuXi XDC’s integrated platform, end-to-end service capability and solid performance.

WuXi XDC will continue to uphold the vision of “Linking Innovation to Health”, accelerate and transform the discovery, development and manufacturing of bioconjugates through a comprehensive open-access platform, and enable our global healthcare partners and benefiting patients worldwide.